Teva Pharmaceuticals USA, Inc recalls
13 recall notices naming Teva Pharmaceuticals USA, Inc since January 2025, in United States. The most recent was published 21 Oct 2026.
Latest recalls (13)
- Teva Pharmaceuticals USA, Inc recalls Metoclopramide TabletsFDAPresence of Foreign Tablets/Capsules
- Teva Pharmaceuticals USA, Inc recalls traZODone Hydrochloride TabletsFDAPresence of Foreign Tablets/Capsules
- Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionFDALack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
- Teva Pharmaceuticals USA, Inc recalls Claravis (isotretinoin capsuleFDAFailed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- Teva Pharmaceuticals USA, Inc recalls Isotretinoin CapsulesFDASuperpotent and Subpotent
- Teva Pharmaceuticals USA, Inc recalls Clonidine Transdermal SystemFDACGMP Deviations: use of an unapproved raw material
- Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionFDALack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the…
- Teva Pharmaceuticals USA, Inc recalls Metoprolol Succinate Extended-Release TabletsFDAFailed Dissolution Specifications
- Teva Pharmaceuticals USA, Inc recalls Carton labelFDADefective Container - A defect in the side-seal which allows leakage of product.
- Teva Pharmaceuticals USA, Inc recalls Amoxicillin and Clavulanate Potassium for Oral Suspension USPFDASubpotent drug; Clavulanate Potassium component
- Teva Pharmaceuticals USA, Inc recalls Prazosin HydrochlorideFDACGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable…
- Teva Pharmaceuticals USA, Inc recalls Metoclopramide TabletsFDAPresence of foreign tablets/capsules.
- Teva Pharmaceuticals USA, Inc recalls Granix (tbo-filgrastim) Injection 300 mcg/0.5 mLFDAFailed Stability Specifications - 12-month stability test result for one of the known peptides is below the specification limit